Fisher & Paykel Healthcare Corporation Limited (NZSX:FPH, ASX:FPH) advises that our Australia based Director Adrienne Clarke, has tendered her resignation to the Board after six years as a Director. The Board has reluctantly accepted her resignation, understanding the changes in professional duties in Australia which have given rise to her resignation.
Chairman, Gary Paykel said “The Board thanks Adrienne Clarke for her valuable contribution to the company during her time as a director of the company and wishes her all the best in her future endeavours”.
The directors of Fisher & Paykel Healthcare Corporation Limited advise that they have appointed Arthur James Morris, 51, as a director of the company effective 20 February 2008. Arthur is an independent director within the meaning of the NZSX Listing Rules.
Dr Morris is a director of DNA Diagnostics and the CEO of Diagnostic Medlab. He is a fellow of the
Royal Australasian College of Pathologists, Australasian Society for Microbiology and the Infectious Diseases Society of America. Dr Morris trained in Dunedin, Invercargill and Auckland before spending 3 years at Duke University Medical Centre, North Carolina, USA, returning to New Zealand in 1994. Dr Morris received his First Class Honours (microbiology) and medical degrees from the University of Otago and his doctoral degree from the University of Auckland.
Contact: Tony Barclay, Company Secretary on +64 9 574 0119. For more information about the company visit www.fphcare.com
About Fisher & Paykel Healthcare
Fisher & Paykel Fisher Healthcare is a leading designer, manufacturer and marketer of products and systems for use in acute and chronic respiratory care, surgery and the treatment of obstructive sleep apnea. The company’s products are sold in more than 120 countries worldwide. For more information about the company, visit our website www.fphcare.com.
Ends
Contact
|